Latest news

• BMS reports strong growth as its Q3 results beat predictions

  up from $24m in Q2, while Breyanzi (lisocabtagene maraleucel), launched this year in lymphoma, had $30m in sales, up from $17m earlier in the year.

• Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

  New results follow success of BMS’ Breyanzi in the same patient population and setting. ... The ongoing TRANSFORM study is evaluating Breyanzi (lisocabtagene maraleucel) compared to current standard of care regimens for LBCL, including high-dose

• BMS’ CAR T therapy Breyanzi shows benefit in B-cell lymphoma study

  Breyanzi demonstrated a statistically significant improvement in event-free survival compared to standard of care. ... The ongoing TRANSFORM study is evaluating Breyanzi (lisocabtagene maraleucel) compared to current standard of care regimens for LBCL,

• Yescarta gains first FDA approval for indolent follicular lymphoma

  Also approved for the treatment of large B-cell lymphoma is Novartis’ rival CAR-T therapy Kymriah (tisagenlecleucel) and Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel), which are both approved

• FDA approves BMS’ blood cancer CAR T therapy after delay

  The FDA's approval of Breyanzi came a year after the start of the review. ... Breyanzi joins other approved CAR T therapies on the market from Gilead/Kite and Novartis.